Brokerages Set OptimizeRx Co. (NASDAQ:OPRX) Price Target at $16.00

Shares of OptimizeRx Co. (NASDAQ:OPRX) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $16.00.

Several brokerages recently weighed in on OPRX. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 price target on shares of OptimizeRx in a research note on Monday, April 1st. JMP Securities reiterated a “market outperform” rating and issued a $16.00 price target on shares of OptimizeRx in a research note on Friday, June 21st. Finally, Stifel Nicolaus reissued a “buy” rating and set a $13.00 price objective on shares of OptimizeRx in a research note on Wednesday, May 15th.

Institutional Trading of OptimizeRx

A number of institutional investors and hedge funds have recently bought and sold shares of the company. AWM Investment Company Inc. increased its position in shares of OptimizeRx by 4.0% during the first quarter. AWM Investment Company Inc. now owns 853,042 shares of the company’s stock valued at $10,364,000 after acquiring an additional 33,000 shares in the last quarter. First Light Asset Management LLC increased its holdings in OptimizeRx by 0.6% in the 1st quarter. First Light Asset Management LLC now owns 1,737,584 shares of the company’s stock worth $21,112,000 after buying an additional 10,286 shares in the last quarter. Vanguard Group Inc. raised its position in OptimizeRx by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock worth $12,482,000 after buying an additional 6,291 shares during the last quarter. Blair William & Co. IL lifted its stake in OptimizeRx by 5.6% during the 1st quarter. Blair William & Co. IL now owns 782,573 shares of the company’s stock valued at $9,508,000 after acquiring an additional 41,469 shares during the period. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of OptimizeRx during the 1st quarter valued at about $1,053,000. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Trading Down 3.1 %

Shares of OPRX opened at $10.00 on Wednesday. OptimizeRx has a 1-year low of $6.92 and a 1-year high of $16.65. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.26. The firm’s 50-day moving average price is $11.11 and its 200-day moving average price is $12.80. The firm has a market capitalization of $182.70 million, a price-to-earnings ratio of -9.80 and a beta of 1.28.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). OptimizeRx had a negative net margin of 23.10% and a negative return on equity of 6.96%. The firm had revenue of $19.69 million for the quarter, compared to the consensus estimate of $18.66 million. During the same period in the previous year, the firm posted ($0.34) earnings per share. Sell-side analysts anticipate that OptimizeRx will post -0.42 EPS for the current year.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.